Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 337-344

  Karthik, Selvaraju ^a   Sankar, Renu ^a   Varunkumar, Krishnamoorthy ^a   Anusha, Chidambaram ^a   Ravikumar, Vilwanathan ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

A549; Bortezomib; NF B; NSCLC; Reactive oxygen species; Romidepsin

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; FLUOROCHROME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PROCASPASE 3; PROCASPASE 8; PROTEIN P50; REACTIVE OXYGEN METABOLITE; RHODAMINE 123; ROMIDEPSIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; BORONIC ACID DERIVATIVE; CASPASE; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; PYRAZINE DERIVATIVE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NF-KAPPA B; PYRAZINES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION, GENETIC;

EID: 84922224793     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.023     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2007, 57:43-66.
2. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide. Burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Karthik S., Sankar R., Varunkumar K., et al. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother 2014, 68:327-334.
4. Zhang Y., Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001, 15:2343-2360.
5. Legube G., Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Rep 2003, 4:944-947.
6. Iwamoto F.M., Lamborn K.R., Kuhn J.G., et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011, 13:509-516.
7. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009, 45:787-795.
8. McGraw A.L. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm 2013, 70:1115-1122.
9. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase Inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
10. Bates S.E., Piekarz R.L. Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?. Cancer J 2007, 13:80-83.
11. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989.
12. Mayo M.W., Denlinger C.E., Broad R.M., et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 2003, 278:18980-18989.
13. Fantin V.R., Richon V.M. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007, 13:7237-7242.
14. Chakraborty A.R., Robey R.W., Luchenko V.L., et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood 2013, 121:4115-4125.
15. Rundall B.K., Denlinger C.E., Jones D.R. Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004, 136:416-425.
16. Dai Y., Rahmani M., Dent P. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, X IAP down-regulation, and c-Jun N-terminal kinase1activation. Mol Cell Biol 2005, 25:5429-5444.
17. Denlinger C.E., Keller M.D., Mayo M.W., et al. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004, 127:1078-1086.
18. Jones D.R., Broad R.M., Comeau L.D., et al. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002, 123:310-317.
19. Vinodhkumar R., Song Y.S., Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharmacother 2008, 62:85-93.
20. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
21. Kim Y.K., Seo D.W., Kang D.W., et al. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem Biophys Res Commun 2006, 347:1088-1093.
22. Chen L.F., Greene W.C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) 2003, 81:549-557.
23. Heider U., von Metzler I., Kaiser M., et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008, 80:133-142.
24. Ruefli A.A., Ausserlechner M.J., Bernhard D., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001, 98:10833-10838.
25. Rosato R.R., Almenara J.A., Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003, 63:3637-3645.
26. Engel R.H., Evens A.M. Oxidative stress and apoptosis: a new treatment paradigm in Cancer. Front Biosci 2006, 11:300-312.
27. Maurya D.K., Nandakumar N., Devasagayam T.P. Anticancer property of gallic acid in A549, a human lung adenocarcinoma cell line, and possible mechanisms. J Clin Biochem Nutr 2011, 48:85-90.
28. Indran I.R., Tufo G., Pervaiz S., et al. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 2011, 1807:735-745.
29. Kumar S. Regulation of caspase activation in apoptosis: implications in pathogenesis and treatment of disease. Clin Exp Pharmacol Physiol 1999, 26:295-303.
30. Chinnaiyan A.M. The apoptosome: heart and soul of the cell death machine. Neoplasia 1999, 1:5-15.
31. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol 2008, 18:165-173.
32. Agostinis P., Buytaert E., Breyssens H., et al. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci 2004, 3:721-729.
33. Liu T., Wu L.Y., Choi J.K., et al. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol 2010, 36:777-784.